🎉 I'm excited to share our @ScienceMagazine study on "Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy". Congrats to all co-authors. @StanfordCVI @StanfordMed @StanfordDeptMed @Stanford_ChEMH @GreenstoneBio doi.org/10.1126/science.aej5…

🫀 New in #EHJCVP When randomization is not enough: divergent β-blocker trials and the illusion of universal causality @elmir1omerovic , @BjornRedfors and colleagues ask why two rigorous trials of β-blockers after myocardial infarction without reduced ejection fraction reached opposite conclusions. REBOOT, with 8505 patients in Spain and Italy, found no significant benefit. BETAMI-DANBLOCK, with 5574 patients in Norway and Denmark, reported a reduction in its composite endpoint (HR 0.85, 95% CI 0.75 to 0.98), driven mainly by fewer non-fatal infarctions. The authors resist the prevailing explanation based on ejection fraction. In BETAMI-DANBLOCK, 85% of participants had preserved EF, whilst the EF 40 to 49% subgroup now put forward as the therapeutic target was itself not significant (HR 0.82, 95% CI 0.65 to 1.02). Drawing on Cartwright and Pearl, they argue that β-blockers have a stable causal capacity, but that its clinical expression depends on the causal environment: CYP2D6 pharmacogenomics, the agents used (metoprolol versus bisoprolol), cultures of care and rehabilitation intensity, and climate and circadian stressors. These mechanisms are offered as prespecifiable, testable hypotheses, and the authors are explicit that they carry no confirmatory weight. They conclude that both trials can be right, each within its causal environment and that β-blockers after MI are conditionally effective rather than universally beneficial or futile 📜Guidelines should evolve cautiously and registry-based phase 4 trials with CYP2D6 genotyping, rehabilitation intensity scoring and geographic and seasonal covariables should test where the benefit is real🪧 🔗doi.org/10.1093/ehjcvp/pvag0… @BiancaRoccaTwt @Massimi78530343 @OtiliaTica1 @doreen_sy @escardio @ESC_Journals

🫀 New in #EHJCVP 🌎🌏🌍May the universal truth rest in peace and us with her? On how to understand inconsistency in and among pharmacological trials Maura Marcucci, Holger J. Schünemann and Federico Germini ask how to read the divergent β-blocker trials after myocardial infarction without reduced ejection fraction: REBOOT found no cardiovascular benefit, whilst BETAMI-DANBLOCK found benefit. ⏩Their answer draws on the GRADE framework. Inconsistency matters when treatment effects differ enough to warrant different decisions for subgroups of patients, and that judgement rests on absolute effects measured against decision thresholds, rather than on statistical heterogeneity alone. They give a worked example. With a baseline risk of 2.4 events per 100 patient-years for the composite of death, MI or heart failure, the BETAMI hazard ratio of 0.79 translates into an absolute risk difference of minus 0.5 events per 100 patient-years. If the threshold for at least a small effect is set at 1 event per 100 patient-years, this estimate sits below it, in line with the neutral trials. The authors advocate a multi-domain approach that separates absolute from relative treatment effects and weighs the risk of inconsistency alongside imprecision, indirectness and the other sources of uncertainty, always with the appropriate subgroup PICO question in mind. 🔗doi.org/10.1093/ehjcvp/pvag0… @BiancaRoccaTwt @Massimi78530343 @OtiliaTica1 @doreen_sy

🫀New in #EHJCVP Should urate-lowering therapy be used to reduce cardiovascular risk beyond gout? In this issue of EHJ–Cardiovascular Pharmacotherapy, @FedericaFogacci, Claudio Borghi et al. examine the role of serum uric acid and urate-lowering therapy across the cardio–renal–metabolic continuum. Elevated serum uric acid is associated with hypertension, coronary artery disease, heart failure, stroke, chronic kidney disease, and mortality. Mendelian randomization studies also suggest a modest causal contribution to blood pressure, coronary disease, and advanced kidney disease. However, clinical trials have not consistently shown fewer cardiovascular events when urate-lowering therapy is added to guideline-directed treatment in asymptomatic hyperuricaemia, stable ischaemic heart disease, chronic heart failure, or chronic kidney disease. The evidence therefore does not support routine urate-lowering therapy solely for cardiovascular prevention in asymptomatic hyperuricaemia. Treatment should remain focused on gout and symptomatic hyperuricaemia, while future phenotype-guided approaches may help identify patients most likely to benefit. 🔗doi.org/10.1093/ehjcvp/pvag0… @BiancaRoccaTwt @OtiliaTica1 @doreen_sy @ESC_Journals @escardio

🫀 The ESC Working Group on Cardiovascular Pharmacotherapy and the Editorial Board of the #EHJCVP warmly congratulate @LindeCecilia on becoming President of the ESC @escardio We look forward to supporting her efforts to advance and implement cardiovascular science, education and patient care across our Community @BiancaRoccaTwt

#ESCCongress let's us meet in person and makes ideas move faster. The social media Editors of European Heart Journal Cardiovascular Pharmacotherapy @Massimi78530343 @doreen_sy and Jessica Schubert met in Munich to plan how we work together over the coming year, with guidance from our Editor-in-Chief @BiancaRoccaTwt and sat down with Lucy Middleton from Oxford University Press to share ideas on how we bring cardiovascular pharmacotherapy to a wider audience More to come: short, practical updates on what is publishing in the journal. #ESCCongress #CVPharmacotherapy @escardio @ESC_Journals

🔥The first Fireside Chat fo #ESCCongress2026— informal, thought-provoking conversations designed to bring experts and the audience closer together. 📚Is AI a friend or a foe for the future of scientific publishing? Great discussion with Dr Jane A. Leopold, Deputy Editor of the New England Journal of Medicine, and Dr Joseph A. Hill, Editor Emeritus of Circulation. 🖥️ Key takeaway: AI is neither purely a friend nor a foe. It is a tool, and its impact will depend on how we use it. AI may fundamentally reshape how we interact with scientific knowledge and data, moving us from static documents to living documents. Technology will evolve rapidly. Preserving trust, integrity, and scientific rigor will remain our responsibility

🫀📚 EHJ – Cardiovascular Pharmacotherapy at #ESC2026! Great to see European Heart Journal – Cardiovascular Pharmacotherapy represented at #ESCCongress2026 in the beautiful setting of Munich 🇩🇪✨ With an Impact Factor of 8.2, a CiteScore of 11.0, and nearly half a million downloads in 2025, EHJ-CVP continues to grow as a leading platform for high-quality research in cardiovascular pharmacotherapy. 💊❤️ Looking forward to an exciting Congress full of science, collaboration and new ideas! @BiancaRoccaTwt @Massimi78530343 @doreen_sy @OtiliaTica1 @escardio @ESC_Journals

New! Online now: Circadian Clock Interaction with HIF1α Mediates Oxygenic Metabolism and Anaerobic Glycolysis in Skeletal Muscle dlvr.it/TThWQH

🚨New in #EHJCVP 💧Kidney function and acid-base status as gatekeepers of diuretic response in chronic heart failure💊 This pre-specified post-hoc analysis of the DEA-HF randomised crossover trial compared three regimens in congestion-refractory HF: IV furosemide alone, furosemide plus oral metolazone, and furosemide plus IV acetazolamide. With eGFR above 30, adding metolazone produced greater natriuresis than furosemide alone or furosemide plus acetazolamide. Below eGFR 30, neither add-on gave extra benefit. Higher serum bicarbonate predicted better natriuretic and diuretic response and more benefit from metolazone. 🛟Safety was comparable across the eGFR range. Although this is a small, single-centre, prespecified post-hoc analysis, the crossover design and mechanistic endpoints still give a set of information useful in daily practice and a strong platform for designing larger confirmatory studies. 🔗doi.org/10.1093/ehjcvp/pvag0… @BiancaRoccaTwt @Massimi78530343 @Costa_F_8 @doreen_sy @OtiliaTica1 @escardio @ESC_Journals

New in #EHJCVP 💊SSRIs are commonly prescribed in patients with coronary artery disease, but what happens after PCI during dual antiplatelet therapy? 🫀 In this large real-world #TriNetX analysis of nearly 30,000 patients, concomitant SSRI use was associated with a higher risk of major bleeding🩸, without an increase in ischaemic events. The study benefits from a large international cohort and propensity-score matching, but its retrospective design leaves room for residual confounding, while prescription data cannot fully capture treatment adherence and persistence of all treatments or bleeding severity. An important contribution highlighting a clinically relevant drug–drug interaction that deserves careful consideration, particularly in patients at high bleeding risk and further prospective studies🔎 🔗doi.org/10.1093/ehjcvp/pvag0… @BiancaRoccaTwt @Massimi78530343 @OtiliaTica1 @Costa_F_8 @escardio @ESC_Journals @doreen_sy

Our latest work is out in @CellReports! Read the press release by the @UZH_ch: news.uzh.ch/en/articles/medi…

@CircRes Compendium on #Lipoproteins and #CVD #CETP Inhibitors: Back with a New Target ahajrnls.org/4vC1yTf Authored by Drs.Nicholls & colleagues @ProfSNicholls @ajnelson @ProfKausikRay @johnkastelein

A note from our Editor-in-Chief, @BiancaRoccaTwt : Few days ago, we held the first meeting of the renewed EHJ-CVP Editorial Board. 🌍Colleagues dialled in from across Asia, Australia, Europe and North America. Some from very late time zones. Honoured to have Prof. Parkhomenko join from Kyiv. Multidisciplinary, global, with strong representation of women across the Board. Exactly the team this journal needs. I left the meeting genuinely energised. There is a lot we want to do together. We are united in purpose and stronger in advocacy for better and inclusive cardiovascular pharmacotherapy. #EHJCVP #Cardiology #ClinicalPharmacology #Pharmacotherapy @ESC_Lavinia @ESC_Journals @escardio @Massimi78530343 @doreen_sy @OtiliaTica1 @Costa_F_8

Impressive quality of submitted science driving the growth of cardiovascular knowledge🚀5869 abstracts&549 clinical cases accepted for #ESCCongress Munich🇩🇪 A huge step forward for science & collaboration🔬 Programme now live—Spread the word Programme is now available online esc365.escardio.org/ESC-Cong… @BiancaRoccaTwt @ESC_Journals @ESC_Camille @Massimi78530343 @doreen_sy @OtiliaTica1 @Costa_F_8

🚨New in EHJ-CVP🚨 HFpEF and HFmrEF therapies continue to evolve rapidly💊 This pre-specified Bayesian analysis of FINEARTS-HF adds another layer to the finerenone story — strengthening the probability of benefit for reducing worsening HF events and CV death across the preserved EF spectrum. How do you see Bayesian analyses influencing the way we interpret HF trials and future guideline adoption?📊 Read the article in EHJ-CVP: 🔗doi.org/10.1093/ehjcvp/pvag0…

📢New in EHJ-CVP: The journal introduces Rapid Communications📜: a new concise article format for focused clinical & translational research🚀 ≤1000 words (excluding references), emphasis on methods/results, 1 figure/table, no abstract or supplementals. Fast, focused, impactful science!🔬 🔗academic.oup.com/ehjcvp/page… @BiancaRoccaTwt @doreen_sy @OtiliaTica1 @Massimi78530343 @Costa_F_8 @ESC_Journals @ESCardioNews

📢The new #EHJCVP issue is now online💥the first under Editor-in-Chief Prof. Bianca Rocca & the new editorial board!✍🏼 From innovation in CV pharmacotherapy to research integrity and cutting-edge science across the field🔬the issue opens with an editorial from EiC, setting the tone for journal's direction➡️ 🔗academic.oup.com/ehjcvp/issu… @BiancaRoccaTwt @doreen_sy @Massimi78530343 @Costa_F_8 @ESCardioNews @ESC_Journals

🆕A new era for #EHJCVP➡️ With this first editorial, we are proud to welcome an international & multidisciplinary Board committed to innovation, diversity, patient-centred care🫀and rigorous science📚 Together, shaping the future of cardiovascular pharmacotherapy🌍💊 🔗doi.org/10.1093/ehjcvp/pvag0…

Excited to start this new journey with #EHJCVP under the new leadership of @EditorEHJCVP. Many innovations ahead !